Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (−/−) Mice-Reference-Cited by-同舟云学术

Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (−/−) Mice

Published:2012-08-23 Issue:3 Volume:343 Page:556-567
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Hambruch Eva,Miyazaki-Anzai Shinobu,Hahn Ulrike,Matysik Silke,Boettcher Alfred,Perović-Ottstadt Sanja,Schlüter Thomas,Kinzel Olaf,Krol Helen Desiree,Deuschle Ulrich,Burnet Michael,Levi Moshe,Schmitz Gerd,Miyazaki Makoto,Kremoser Claus

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference64 articles.

1. Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists

2. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice;Agellon;J Biol Chem,1991

3. Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor

4. Decreased Atherosclerosis in Heterozygous Low Density Lipoprotein Receptor-deficient Mice Expressing the Scavenger Receptor BI Transgene

5. Endothelial Lipase Concentrations Are Increased in Metabolic Syndrome and Associated with Coronary Atherosclerosis

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of hepatic bile salt uptake by Bulevirtide reduces atherosclerosis in Oatp1a1 Ldlr mice;Journal of Lipid Research;2024-08

2. Multiomics to Characterize the Molecular Events Underlying Impaired Glucose Tolerance in FXR-Knockout Mice;Journal of Proteome Research;2024-07-05

3. Dose Prediction and Pharmacokinetic Simulation of XZP-5610, a Small Molecule for NASH Therapy, Using Allometric Scaling and Physiologically Based Pharmacokinetic Models;Pharmaceuticals;2024-03-13

4. Development of Cilofexor, an Intestinally-Biased Farnesoid X Receptor Agonist, for the Treatment of Fatty Liver Disease;Journal of Pharmacology and Experimental Therapeutics;2024-02-26

5. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid;Medicinal Research Reviews;2023-10-30